As China’s national anti-corruption campaign enters a new stage and goes deep into the local level, physicians in the country are becoming increasingly cautious about issuing prescriptions for high-value drugs, particularly in the oncology area.
In July, Beijing launched a massive clampdown on commercial and prescription irregularities in the health sector, affecting all aspects of the supply chain and including
Although many initially believed the campaign was targeting high-profile hospital presidents with the authority to procure and approve large purchases of drugs and devices, now it seems official attention is turning to physicians and their prescriptions,